{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-037183","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.050081+00:00","generated_at":"2026-05-31T09:21:22.103657+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Absci Q2 2024: revenue $1.3M, net loss $24.8M; ABS-101 half-life 2-3x; MSK collab","bullets":["Q2 revenue $1.3M (down from $3.4M YoY); net loss $24.8M vs $41.7M (incl. $21.3M non-cash impairment in prior year).","Cash, cash equivalents and short-term investments $145.2M; expects runway into H1 2027.","ABS-101 NHP data: 2-3x extended half-life vs clinical anti-TL1A antibodies; 200 mg/mL formulation supports subcutaneous.","Entered collaboration with Memorial Sloan Kettering to co-develop up to 6 novel oncology therapeutics using generative AI.","Anticipates Phase 1 start for ABS-101 in early 2025; interim data readout expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-037183","json":"https://secwatch.observer/filing/0001628280-24-037183.json","markdown":"https://secwatch.observer/filing/0001628280-24-037183.md","text":"https://secwatch.observer/filing/0001628280-24-037183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024037183/0001628280-24-037183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024037183/absc-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:21:22.103657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}